95,960 Johnson & Johnson $JNJ Shares Bought by Private Advisor Group LLC

Johnson & Johnson logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Private Advisor Group increased its Johnson & Johnson stake by 34.6% in the third quarter, buying 95,960 shares and bringing its holding to 373,648 shares, valued at about $98.9 million.
  • J&J reported quarterly EPS of $2.59, beating estimates of $2.53, while revenue rose 5.9% year over year to $25.40 billion. The company set 2026 EPS guidance of $11.05–$11.15.
  • Analysts’ consensus rating is Moderate Buy, with an average price target of $275.92. Separately, two executives reported stock sales, including EVP Elizabeth Forminard’s sale of 13,072 shares.
  • Interested in Johnson & Johnson? Here are five stocks we like better.

Private Advisor Group LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 34.6% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 373,648 shares of the company's stock after purchasing an additional 95,960 shares during the quarter. Private Advisor Group LLC's holdings in Johnson & Johnson were worth $98,920,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Tyche Wealth Partners LLC lifted its stake in shares of Johnson & Johnson by 41.2% in the 3rd quarter. Tyche Wealth Partners LLC now owns 31,618 shares of the company's stock worth $8,371,000 after purchasing an additional 9,219 shares during the period. Taylor Hoffman Capital Management LLC increased its holdings in Johnson & Johnson by 0.4% during the third quarter. Taylor Hoffman Capital Management LLC now owns 31,107 shares of the company's stock valued at $8,235,000 after buying an additional 135 shares during the last quarter. Ieq Capital LLC boosted its stake in shares of Johnson & Johnson by 3.7% during the 3rd quarter. Ieq Capital LLC now owns 317,488 shares of the company's stock worth $84,052,000 after acquiring an additional 11,343 shares during the last quarter. Focus Advisor Solutions LLC grew its position in shares of Johnson & Johnson by 48.6% during the 3rd quarter. Focus Advisor Solutions LLC now owns 70,070 shares of the company's stock valued at $18,551,000 after acquiring an additional 22,901 shares during the period. Finally, BHK Investment Advisors LLC purchased a new stake in Johnson & Johnson in the third quarter worth about $203,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Elizabeth Forminard sold 13,072 shares of the company's stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the transaction, the executive vice president directly owned 16,994 shares of the company's stock, valued at $4,832,923.66. This represents a 43.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares of the company's stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.16% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on JNJ shares. Citigroup raised their price target on Johnson & Johnson from $298.00 to $303.00 and gave the company a "buy" rating in a report on Monday, October 5th. HSBC boosted their price target on shares of Johnson & Johnson from $290.00 to $320.00 and gave the stock a "buy" rating in a research note on Thursday, September 10th. Morgan Stanley dropped their price objective on shares of Johnson & Johnson from $294.00 to $292.00 and set an "overweight" rating for the company in a report on Thursday, October 15th. Johnson Rice cut Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Wednesday, October 21st. Finally, UBS Group set a $270.00 target price on Johnson & Johnson in a research report on Wednesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $275.92.

View Our Latest Analysis on Johnson & Johnson

More Johnson & Johnson News

Investors following JNJ have been watching these news items:

  • Positive Sentiment: J&J submitted an FDA application to expand CAPLYTA’s use to manic or mixed episodes associated with bipolar I disorder. Two Phase 3 trials showed symptom improvement versus placebo; approval would add a potential fifth adult indication and broaden the drug’s commercial opportunity. Article: Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA
  • Neutral Sentiment: Recent coverage also highlighted J&J as a long-established dividend payer, which supports its appeal to income-focused investors but offers little new company-specific information about near-term earnings. Article: Reliable Retirement Income Dividend Stocks
  • Negative Sentiment: Recent coverage also associated a prior decline in JNJ shares with insider selling, which can add near-term pressure on investor sentiment. Article: JNJ Stock Price Down Following Insider Selling

Johnson & Johnson Trading Down 2.1%

Shares of NYSE JNJ opened at $272.75 on Thursday. Johnson & Johnson has a 1-year low of $199.38 and a 1-year high of $290.25. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. The business's 50 day moving average is $267.42 and its two-hundred day moving average is $250.61. The stock has a market capitalization of $656.58 billion, a P/E ratio of 41.33, a PEG ratio of 2.75 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The business had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. During the same period last year, the company earned $2.80 EPS. The company's revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, research analysts expect that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson's dividend payout ratio is currently 81.21%.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Johnson & Johnson Right Now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines